Skip to main content

Table 1 Patient characteristics at baseline

From: Clinical course and outcomes of type-2 diabetic patients after treatment intensification for insufficient glycaemic control - results of the 2 year prospective DiaRegis follow-up

  Patients included (n = 3810) Patients with a 2 year FU* (n = 3058)
Age (years) 65.9 (57.6–72.9) 66.1 (57.7–72.9)
Female gender (%) 46.7 46.7
Body weight (kg) 88 (78–100) 88 (78–100)
Diabetes duration (years) 5.5 (2.9–9.4) 5.6 (2.9–9.4)
Lipid values   
 LDL-C (mg/dL) 120 (98–145) 119 (96–145)
 HDL-C (mg/dL) 47 (40–57) 47 (40–56)
 TG (mg/dL) 176 (127–242) 175 (127–241)
 TC (mg/dL) 204 (175-232) 211 (181-235)
Blood pressure (mmHg) 137/80 137/80
Blood glucose   
 HbA1c (%) 7.4 (6.8–8.3) 7.4 (6.8–8.2)
 FPG (mg/dL) 142 (119–171) 141 (119–169)
 PPG (mg/dL) 185 (155–221) 183 (155–220)
Hypoglycaemia requiring assistance (%) 1.2 1.4
Concomitant disease (%)   
 Prior MI (%) 6.0 5.8
 Prior stroke/TIA (%) 4.6 4.8
 HF (%) 9.9 9.9
 PAD (%) 6.0 6.2
 Prior amputation (%) 0.9 0.9
 Any neuropathy (%) 15.9 14.5
 Any retinopathy (%) 4.2 4.2
 Vascular disease (%)** 24.0 24.3
Cardiovascular pharmacotherapy   
 ACEi 50.0 50.5
 ARB 21.8 21.9
 Betablocker 46.6 46.5
 CCB 24.9 25.4
 Diuretic 41.2 42.0
 ASA 33.6 33.8
 Statin 42.2 42.6
Antidiabetic therapy post baseline   
 Metformin (%) 84.5 84.5
 Sulfonylureas (%) 26.2 27.2
 Glucosidase inhibitors (%) 2.3 2.6
 Glinides (%) 6.0 5.3
 DPP-4 inhibitors (%) 38.8 39.3
 Glitazones (%) 10.3 10.1
 GLP-1 analogues (%) 9.2 9.7
 Insulin (%) 17.3 17.6
  1. Legend: *Including those that died during follow-up; **vascular disease includes CAD, prior stroke/TIA, and/or PAD; FU, follow-up; TG, triglycerides; FPG, fasting plasma glucose; PPG, postprandial plasma glucose; MI, myocardial infarction; TIA, transitory ischemic attack; HF, heart failure; PAD, peripheral artery disease; ACEi, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; CCB, calcium channel blocker; ASA, acetylsalicylic acid; DPP, dipeptidylpeptidase; GLP, glucagon-like peptide; SU, sulfonylurea.